Amyloid Assembly and Cerebral Endothelial Cells Response

Principal Investigator
Agueda Rostagno, PhD
New York University Grossman School of Medicine
New York, NY, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$299,959
Active Dates
April 01, 2004 - March 31, 2007
Grant ID
A2004017
Summary
Cerebral Amyloid Angiopathy (CAA) is the generic name for a large group of diseases characterized by the presence of amyloid beta fibrils (Aß) in small vessels and medium-sized arteries and arterioles in the brain. Although Aß is the most common CAA amyloid, many other proteins have been associated with the formation of amyloid deposits in the brain. Some of these proteins are cystatin C, transthyretin, gelsolin, and the recently described ABri and ADan peptides. The ABri and ADan peptides are associated with two rare hereditary conditions—familial British and Danish dementias—that are characterized by extensive CAA and Alzheimer’s-like neurodegeneration. This is an indication that different amyloid molecules may lead to the same scenario of neuronal loss and dementia. Dr. Rostagno’s is working with fibrils and pre-fibrils of various amyloid molecules and the hereditary variants involved in the production of CAA in cultures. These compounds will be fed to human cerebral endothelial cells in culture, and their toxicity as well as their ability to induce inflammation will be assessed by biochemical analysis. It is hoped that an understanding of the molecular events triggered by the toxic peptides will lead to the design and development of new treatments to modulate these cellular processes and ameliorate the impact of these neurological diseases.
Grants
Related Grants
Alzheimer's Disease Research
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Olav Andersen, PhD
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026

Principal Investigator
Olav Andersen, PhD
Alzheimer's Disease Research
The Role of DYRK1A in Altered Microglia Biology in a Cellular Model of Alzheimer’s Disease in Down Syndrome
Active Dates
January 01, 2025 - December 31, 2027
Principal Investigator
Frances Wiseman, PhD
The Role of DYRK1A in Altered Microglia Biology in a Cellular Model of Alzheimer’s Disease in Down Syndrome
Active Dates
January 01, 2025 - December 31, 2027

Principal Investigator
Frances Wiseman, PhD
Alzheimer's Disease Research
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD